Psychosexual consequences of risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers.

Completed

• Conditions: menopausal transition.; Menopause; 10014701; 10033283

• Registration Number: NL-OMON40602
• Lead Sponsor: niversitair Medisch Centrum Groningen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 124

Inclusion Criteria

All women who underwent risk-reducing salpingo-oophorectmy (RRSO) at the UMCG and who were younger than 52 years at the time of RRSO, have no active cancer at the time of inclusion and report two or more moderate to severe menopause related complaints (see researchprotocol, paragraph 4.2).

Exclusion Criteria

Women will be excluded from the study if they have no sufficient mastery of the Dutch language, if they suffer from severe cognitive or psychiatric problems.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>As the primary parameter, the MENQOL will be used to assess menopause-specific<br /><br>quality of life in the MBSR and control group at baseline to twelve weeks. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>As the secondary parameters, the MENQOL will be used to assess<br /><br>menopause-specific quality of life in the MBSR and control group at baseline to<br /><br>six and twelve months. Furthermore as secondary parameters the female sexual<br /><br>function index questionnaire (FSFI) and female sexual distress scale<br /><br>questionnaire (FSDS) will be used to assess sexual functioning and sexual<br /><br>distress in the MBSR and control group at baseline to twelve weeks, six months<br /><br>and twelve months. </p><br>